Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | XIAP | P98170 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PLTP | P55058 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283651 | 0.88 | RORC (0.67) | ADORA2AADORA1ADORA3ADORA2BRORC | |
| SCHEMBL2753572 | 0.81 | RORC (0.74) | ADORA2AADORA1ADORA3ADORA2BRORC | |
| SCHEMBL2752606 | 0.80 | ALDH1A1 (0.74) | ADORA2AADORA1LMNARORCPTGS2 | |
| SCHEMBL6286094 | 0.80 | ALDH1A1 (0.73) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL10254354 | 0.79 | PTGS2 (0.61) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL6276729 | 0.78 | ADORA1 (0.62) | ADORA2AADORA1ADORA3ADORA2BRORC | |
| SCHEMBL2753574 | 0.77 | RORC (0.65) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL18015884 | 0.77 | PTGS2 (0.55) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL6546414 | 0.75 | ALDH1A1 (0.56) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL6546740 | 0.75 | MAPT (0.63) | ADORA3ADORA2BLMNAPTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | ADORA2A 1487/4885ADORA1 1594/4885ADORA3 1613/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | ADORA2A 1689/4885ADORA1 2218/4885ADORA3 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.